

ASX ANNOUNCEMENT

9 April 2026

Change to Clarity's Board of Directors

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, announces that its Executive Director, Dr Colin Biggin, is stepping down from the Board. He will continue in his role as Chief Operating Officer (COO) of Clarity.

Dr Biggin joined Clarity over nine years ago and his background in radiopharmaceutical development is extensive, with over 20 years in the industry, including his experience at Algeta ASA (Algeta) from 2006 up to Algeta's acquisition by Bayer for US\$2.9 billion in 2014. He was significantly involved in the development and launch of Xofigo, Algeta's lead radiopharmaceutical product targeting metastatic prostate cancer.

Clarity's Executive Chairperson, Dr Alan Taylor, commented, "This change at Board level is aligned with our commitment to strong corporate governance as prescribed in the Australian Securities Exchange (ASX) *Corporate Governance Principles and Recommendations*. To date, given our stage of development and the highly specialised knowledge base required to operate in the radiopharmaceutical sector, we have determined that the best way to structure the Board to be effective and add value has been to retain more than one Executive Director. As the Company prepares for commercial launch, it is increasingly important to build a strong independent presence at Board level. We will continue to work in this direction, seeking high-calibre independent leaders, with a mix of expertise and experience relevant to our requirements, to join Clarity's Board."

"We want to thank Colin for his assistance at the Board level for over six years. He has been a great contributor over that time and will continue delivering at the executive level towards our shared goal of improving treatment outcomes for people with cancer."

Dr Biggin commented, "It is an exciting time for Clarity as we are progressing through registrational trials towards commercialisation in indications with high unmet need and building a supply and manufacturing strategy to support commercial-scale product launch. This is testament to the Company's outstanding technology, commitment to high quality of science and, importantly, an outstanding team. I have thoroughly enjoyed my time as an Executive Director over the last 6+ years and remain committed to the Company's success in my role as COO and as a member of the senior executive team. It is great to see Clarity move toward this next stage of commercialisation, and I look forward to working with our team to enable a successful implementation of the strategy."

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancers.

www.claritypharmaceuticals.com

For more information, please contact:

Clarity Pharmaceuticals

Dr Alan Taylor

Executive Chairpersonataylor@claritypharm.com

Lisa Sadetskaya

Director, Corporate Communicationslisa@claritypharm.com

This announcement has been authorised for release by the Executive Chairperson.